PMN Stock Forecast & Price Target

ProMIS Neurosciences Inc. is poised for significant growth, driven by the advanced development of its Alzheimer's candidate, PMN310, which is over 85% enrolled in the Phase Ib PRECISE-AD study. The company's innovative approach with its thermodynamic, computational discovery platform has resulted in a favorable safety profile for PMN310, outperforming existing anti-amyloid antibodies in terms of incidence of amyloid-related imaging abnormalities (ARIA). Additionally, the substantial and rapidly growing market for Alzheimer’s therapies presents a compelling commercial opportunity for ProMIS as it approaches key clinical milestones and unveils promising efficacy data.

ProMIS Neurosciences Inc reported a significant net loss of $11.6 million in 3Q25, which raises concerns about the company's financial sustainability in a highly competitive sector. The potential risks surrounding its lead product, PMN310, include the inability to demonstrate safety and efficacy compared to existing treatments, as well as challenges in achieving regulatory approval, particularly in the U.S. Additionally, the company faces the prospect of near-term dilution due to the ongoing need for financing until it achieves cash flow positivity, compounding the uncertainty surrounding its market position and growth potential.